Search results
Super Common Health Conditions Can Make a Heat Wave More Dangerous: Here's How to Prepare
CNET· 4 days agoA heat wave is set to stifle parts of the US this week, with people across the Midwest and Northeast...
Cryogenic chambers and infrared capsules. This ‘fitness hotel’ is taking wellness tech to the next...
CNN.com· 21 hours agoEditor’s Note: This CNN series is, or was, sponsored by the country it highlights. There are...
How To Get Rid Of (And Prevent) Chin Acne
Women's Health via Yahoo News· 3 days agoChin acne can be caused by your diet, hygiene practices, hormones, and plenty of other factors. Experts explain how to fight and prevent it in the first...
IgG4-Related Disease Affects Men More Often, More Severely
Medscape· 2 days agoA recent study highlighted sex-based differences in manifestations of IgG4-related disease.
Little Rock Black-owned business reflects on history ahead of Juneteenth
KTHV Little Rock· 3 days agoAhead of Juneteenth, one Little Rock Black-owned business is reflecting on history. Specifically,...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 1 day agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
Izokibep Enthesitis Benefit Lacking in Phase 2b/3 PsA Trial
Medscape· 3 days agoThe primary efficacy endpoint was met, but the novel small molecule therapeutic did not reduce...
Can High Cortisol Levels Cause Weight Gain?
MediaFeed via AOL· 2 days agoElevated cortisol levels can trigger various physical, emotional and behavioral symptoms. (These can indicate other health concerns, though, so keep that...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 3 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,